Neuroreplacement of Degenerative Cholinergic Cells
About the Research Project
Program
Award Type
Standard
Award Amount
$99,990
Active Dates
April 01, 2004 - February 28, 2007
Grant ID
A2004226
Summary
Cholinergic neurons, which are closely associated with memory function, selectively degenerate in Alzheimer’s disease (AD). Dr. Qu’s previous research has demonstrated that transplanted human neural stem cells (hNSCs) migrate to the proper sites and differentiate into the proper cell types to replace lesioned cholinergic neurons in the brain. Therefore, the transplantation of hNSCs may be a good candidate as a cholinergic cell replacement therapy for AD. Dr. Qu has found that transplanting hNSCs to aged (24-month-old) rats improved behavioral impairment as measured in the Morris water maze. He was also able to show that neurons and glia derived from the transplanted cells were present in several areas of the host brain. Dr. Qu’s behavioral research is now investigating the effects of hNSC transplantation on the cognitive function of brain-lesioned animals using several different types of mazes. It is hoped that this research will provide valuable data to assess the effectiveness of human neural stem cell transplantation as a means to replace degenerative cholinergic neurons in the central nervous system.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD